TABLE 6.1 (
Continued
)
Gene
Protein name Tissue distribution
Substrate properties
Selected inhibitor
and (inducer)
Driving force
SLC21A9/
SLCO2B1
OATP-B,
OATP-RP2,OATP2B1
Liver, intestine,
pancreas, lung,ovary, testes, spleen
SLC21A11/
SLCO3A1
OATP-D,
OATP3A1
Ubiquitous (strong
expression inleukocytes spleen),cancer cells
SLC21A12/
SLCO4A1
OATP-E,
OATP-RP1,OATP4A1
Ubiquitous (mainly
in skeletal muscles),cancer cells
SLC22A1
OCT1
Liver
Small organic cationsTetraethylmethylammonium
(TEA), MPP
+
, metformin,
azidothymine (AZT),choline
Tetraethylmethylammonium,
cimetidine, and HIVinhibitors
SLC22A2
OCT2
Kidney, brain
OCT2 is driven
by membranepotential
SLC22A3
OCT3, EMT Skeletal muscle,
liver, placenta,kidney, heart
Small organic cationsTEA, dopamine,
guanidine
SLC22A4
OCTN1
Kidney, skeletal
muscle, prostate,placenta, heart
Small organic cations
TEA, verapamil,
imipramine,nicotine, procainamide
OCTN1 is driven
by H
+
144